Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01204931 · ClinicalTrials.gov registry record
Can We Predict Who Has Gastroesophageal Reflux Disease (GERD)?
A clinical trial, sponsored by Vanderbilt University.
- Completed
- Registry status
- 254
- Enrollment target
NCT01204931 is a clinical trial that has completed, run by Vanderbilt University. The registered enrollment target is 254 participants.
The verdict
NCT01204931 has completed, sponsored by Vanderbilt University.
- COMPLETED
- Registry status
- 254 participants
- Enrollment target
Study Summary
Gastroesophageal reflux disease (GERD) is currently defined as "a condition which develops when the reflux of stomach contents causes troublesome symptoms and/or complications". Doctors often diagnose and treat GERD based on symptoms of heartburn and regurgitation. In recent years, the prevalence of partial or non-response to Proton Pump Inhibitors (PPI) has increased resulting in diagnostic testing with esophagogastroduodenoscopy (EGD) or ambulatory pH monitoring. Most patients do not have endoscopic evidence for reflux. Thus, in this group pH monitoring has emerged as an important physiologic test to determine the degree of esophageal acid exposure and to assess the association between patients' persistent symptoms and acid reflux events. The aims of this study are to assess the sensitivity and specificity of symptom associated indices and determine the best parameter for predicting GERD from a list of conventional pH measurement findings.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 254 participants |
| Start Date | 2010-11 |
| Est. Completion | 2015-06 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01204931
The ClinicalTrials.gov registry entry for NCT01204931 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 254 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vanderbilt University, which has 430 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT01204931 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01204931 about?
NCT01204931 is a clinical study titled "Can We Predict Who Has Gastroesophageal Reflux Disease (GERD)?". Gastroesophageal reflux disease (GERD) is currently defined as "a condition which develops when the reflux of stomach contents causes troublesome symptoms and/or complications". Doctors often diagnose and treat GERD based on symptoms of heartburn and regurgitation. In recent years, the prevalence of...
What is the current status of trial NCT01204931?
This trial is currently completed. The enrollment target is 254 participants. The study started on 2010-11. Estimated completion is 2015-06.
Who is sponsoring clinical trial NCT01204931?
This trial is sponsored by Vanderbilt University, which has 430 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.